I
t is now clear that reactive oxygen species (ROS) are involved in the genesis of experimental hypertension. Superoxide (O 2 ·− ) production is increased in the vasculature, kidney, and central nervous system in various models of hypertension, 1, 2 and scavenging O 2 ·− using membrane-targeted forms of superoxide dismutase (SOD) or SOD mimetics blunts hypertension in these models. 3, 4 The NADPH oxidases are major sources of ROS in hypertension. The catalytic subunits of these enzymes are the Nox proteins, which facilitate transfer of electrons from NADPH to molecular oxygen to form O 2 ·− . There are 5 Nox proteins, which vary in their means of activation, subunit binding partners, and output of O 2 ·− . Genetic deletion of the NADPH oxidase subunits Nox1, Nox2, and p47 phox prevents many of the consequences of angiotensin II and renal artery stenosis, including elevation of blood pressure, increased renal vascular resistance, and endothelial dysfunction. [5] [6] [7] All Nox proteins, except Nox 5, which does not exist in rodents, require the small membrane subunit p22 phox .
Angiotensin II increases vascular p22
phox expression in vivo, and deletion of p22 phox in vascular smooth muscle cells prevents ROS formation and the growth response to angiotensin II. 8, 9 Conversely, transgenic overexpression of vascular smooth muscle p22
phox enhances hypertension and vascular smooth muscle hypertrophy, in response to angiotensin II. 10 Recently, it has been recognized that ROS production is increased in several regions of the brain in hypertension, including the circumventricular organs, 11 hypothalamic centers, and the brainstem. 12 ROS increase neuronal firing in these regions, and ultimately increases sympathetic outflow. The subfornical organ (SFO) is particularly important in modulating these responses. This region is rich in angiotensin type 1 receptors, and is a major cardiovascular regulatory and dipsogenic center in the brain. 13, 14 Intracerebroventricular (ICV) administration of adenoviruses overexpressing SOD blunts the acute pressor effects of angiotensin II in the SFO, and in the long-term, prevents the hypertension caused by chronic angiotensin II infusion. 11, 15 Recent studies have shown that both Nox2 and Nox4 are involved in the acute pressor response to angiotensin II, whereas the dipsogenic response is dependent on Nox2. 16 Likewise, ICV administration of an adenovirus expressing a dominant-negative form of the small G-protein, Rac1, prevents the acute pressor and water-drinking Abstract-Reactive oxygen species and the NADPH oxidases contribute to hypertension via mechanisms that remain undefined.
Reactive oxygen species produced in the central nervous system have been proposed to promote sympathetic outflow, inflammation, and hypertension, but the contribution of the NADPH oxidases to these processes in chronic hypertension is uncertain. We therefore sought to identify how NADPH oxidases in the subfornical organ (SFO) of the brain regulate blood pressure and vascular inflammation during sustained hypertension. We produced mice with loxP sites flanking the coding region of the NADPH oxidase docking subunit p22 phox . SFO-targeted injections of an adenovirus encoding cre-recombinase markedly diminished p22 phox , Nox2, and Nox4 mRNA in the SFO, as compared with a control adenovirus encoding redfluorescent protein injection. Increased superoxide production in the SFO by chronic angiotensin II infusion (490 ng/ kg min -1 ×2 weeks) was blunted in adenovirus encoding cre-recombinase-treated mice, as detected by dihydroethidium fluorescence. Deletion of p22 phox in the SFO eliminated the hypertensive response observed at 2 weeks of angiotensin II infusion compared with control adenovirus encoding red-fluorescent protein-treated mice (mean arterial pressures=97±15 versus 154±6 mm Hg, respectively; P=0.0001). Angiotensin II infusion also promoted marked vascular inflammation, as characterized by accumulation of activated T-cells and other leukocytes, and this was prevented by deletion of the SFO p22 17 The roles of Nox2, Nox4, and Rac1 in chronic hypertension have not been defined in these acute studies.
In the present study, we sought to definitively define the role of NADPH oxidases in the SFO in hypertension caused by prolonged angiotensin II infusion. To accomplish this, we created mice with loxP sites flanking the coding region of p22 phox , and used cre/lox technology to delete this molecule in the SFO. Our findings show that p22 phox in the SFO is essential for hypertension and vascular inflammation caused by angiotensin II.
Materials and Methods

Creation of p22
phox/flox Mice A targeting vector was created in which a neomycin cassette flanked by loxP sites was cloned into an Apo1 site 7.1-kb upstream of the p22 phox transcription start site. An additional loxP site was placed in intron 1. This was microinjected into embryonic stem cells, and proper homologous recombination was confirmed using Southern blots. Mice containing this targeted mutation were produced using standard techniques and backcrossed to C57Bl/6 mice for >11 generations. These mice were viable, developed normally, and had normal growth. All studies were performed according to a protocol approved by Emory and Cornell Universities Institutional Animal Care and Use Committees. For detailed Material and Methods, please see the online-only Data Supplement.
Results
Effect of Adenovirus Encoding Cre-Recombinase on p22 phox mRNA and O 2 ·− Production in the SFO
In previous studies, we and others found that uptake of adenovirus after SFO-targeted ICV injection is greatest in the SFO, with uptake in other circumventricular organs to be limited to ependymal cells. 18 We therefore focused on the SFO for measurements of p22 phox mRNA and O 2 ·− production in the present studies. Quantitative real-time PCR on punch biopsies of the SFO showed markedly reduced p22 phox mRNA after injection of adenovirus encoding cre-recombinase (AdCre), as compared with adenovirus encoding red-fluorescent protein (AdRFP) control injection, confirming successful targeting ( Figure 1A ). Interestingly, this was accompanied by a marked downregulation of Nox2 and Nox4 mRNA at baseline, and after 14 days of angiotensin II infusion ( Figure 1A and Figure  S1 in the online-only Data Supplement). Real-time PCR also revealed low levels of Nox1 in the SFO after 14 days angiotensin II in mice injected with AdRFP, and this was unchanged by AdCre injection (data not shown).
To investigate whether deletion of p22 phox reduces O 2 ·− production in the SFO, we performed dihydroethidium staining using confocal microscopy and measured fluorescence at 405 nm. In keeping with previous studies, 11 angiotensin II increased dihydroethidium fluorescence in the SFO of AdRFP-injected mice, and this was markedly reduced in mice that had received ICV AdCre ( Figure 1B and 1C) .
Effect of SFO p22
phox Deletion on Hemodynamics
In mice treated with AdRFP, angiotensin II infusion caused a progressive increase in blood pressure to a value of 154±6 mm Hg. In striking contrast, mice with SFO deletion of p22 phox had blood pressure that rose transiently at days 1 to 4 of angiotensin II infusion and then returned to normal values (Figure 2A ).
To investigate whether deletion of p22
phox in the SFO affects sympathetic activity, we performed power spectral analysis of mean arterial pressure. Blood pressure oscillations are influenced by sympathetic and parasympathetic neurons, the renin-angiotensin system, and vasoactive factors like nitric oxide. Power spectral analysis was used to detect which factors are influencing the blood pressure. Sympathetic outflow modulates low-frequency oscillations (0.015-0.6 Hz), thus absolute values divided by the total power of low-frequency provides an indirect measurement of sympathetic outflow. 19 The power of low-frequency blood pressure oscillations was significantly increased after 14 days of angiotensin II infusion in AdRFP-injected mice, but not in mice with SFO deletion of p22 phox by AdCre ( Figure 2B ). Heart rate was diminished by SFO p22 phox deletion before and during angiotensin II infusion. Power spectral analysis phox in the subfornical organ (SFO) and its effect on reactive oxygen species (ROS). Real-time PCR confirmed diminished p22 phox mRNA in the SFO after 14 days of angiotensin II infusion in mice that were injected with an adenovirus encoding cre-recombinase (AdCre). Levels of p22 phox mRNA were normalized to 18S RNA (A, n=5, 2 brains per n). Mice injected with AdCre showed blunted dihydroethidium staining after 14 days of angiotensin II infusion compared with control mice (B, n=5). Densitometry is shown in C.
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of heart rate variability showed that angiotensin II increased the low-frequency/high-frequency ratio in AdRFP-treated, but not AdCre-treated, mice.
Effect of p22 phox Deletion in the SFO on Vascular Inflammation
Flow cytometric analysis indicated that angiotensin II infusion promoted vascular inflammation, as reflected by infiltration CD45 + ( Figure S2A ) and CD3 + ( Figure 3A ) cells detected in single-cell suspensions of vascular homogenates from AdRFPtreated mice. Moreover, the infiltrating T-cells expressed the early activation marker CD69 ( Figure 3B ) and CD44 high ( Figure  S2B ), characteristic of effector memory T-cells. Deletion of p22 phox in the SFO virtually eliminated the increase in vascular leukocytes, including CD69 + and CD44 high T-cells.
Effect of p22 phox Deletion in the SFO on Vascular NADPH Oxidase Expression
To determine whether deletion of p22 phox or angiotensin II in the SFO affects vascular NADPH oxidase subunits, we measured levels of p22 phox and Nox2 mRNA in the aorta. There was no change in p22 phox or Nox2 expression in vehicle-infused mice ( Figure 4A and Figure S3A ). Vascular p22 phox and Nox2 mRNA expression was upregulated in the aortas of both AdCre-and AdRFP-injected mice after 14 days of angiotensin II infusion. As in other studies, 20, 21 we observed a trend of reduced aortic Nox4 mRNA expression in response to angiotensin II; however, this did not reach statistical significance ( Figure S3B ).
Previous studies from our group and others have shown that angiotensin II stimulates vascular preproendothelin-1 mRNA expression. 22 We confirmed this in the present study, and found that this was unaffected by deletion of SFO p22 phox ( Figure 4D ). These data suggest that angiotensin II directly affects vascular p22 phox , Nox2, and endothelin-1 expression, independent of sympathetic outflow or pressure increases.
Discussion
In the present study, we used cre-lox methodology to specifically delete p22 phox in the SFO and showed that this reduced O 2 ·− in this region. Moreover, deletion of p22 phox in this brain region attenuated the hypertensive response and eliminated the vascular inflammation caused by angiotensin II. This study definitively identifies a critical role of the NADPH oxidases in the brain SFO, in this form of experimental hypertension.
Our findings are in agreement with previous reports showing that augmenting SOD or inhibiting Rac-1 activity in the SFO reduces the acute pressor and dipsogenic responses to ICV injections of angiotensin II. 17, 18 Previous studies by Peterson et al showed that silencing either Nox2 or Nox4 blocks the acute pressor response to angiotensin II. Silencing Nox2 also prevented the dipsogenic response to angiotensin II, but silencing Nox4 did not. 16 Although it has been shown that augmenting SOD in the SFO inhibits chronic angiotensin II hypertension, 11 our current study extends this previous observation by specifically identifying a critical role of the NADPH oxidases in the SFO in the long-term effect of angiotensin II.
In these experiments, we specifically targeted p22 phox for selective deletion in the SFO. Although this subunit of the NADPH oxidase is not catalytically active, it is critical for functioning of all Nox isoforms. In the case of Nox2 activation, the proline-rich area in the C-terminal region of p22 phox serves as a docking unit for activated p47 phox . 23 This region also binds p40 phox , which activates Nox2 and competes for p47 phox binding. 24 Moreover, p22 phox associates with and stabilizes the ). A, Mean arterial pressures recorded during the 2 weeks of angiotensin II infusion (n=5). Results from power spectral analysis of mean arterial pressure and heart rate are depicted in B. Baseline data was average from day 3 to day 0 of blood pressure recordings. Angiotensin II represents days 13 and 14 of angiotensin II infusion, to reflect the maximal blood pressure response (n=5). Heart rate before and during angiotensin II treatment is shown in C (n=5), and power spectral analysis of heart rate variability is depicted in D (n=5). Nox2 during processing and transport to the cell membrane. 25 A similar role for Nox1 likely exists, in that we previously found overexpression of p22 phox in transgenic mice markedly increased Nox1 expression. 26 Nox1 associates with p22 phox , 27 and point mutations in the proline-rich region of p22 phox inhibit Nox1 function. 28 Likewise, p22 phox binds Poldip2, a newly recognized activator of Nox4. 29 Thus, our deletion of p22 phox in the SFO should have functionally disabled all Nox isoforms.
In a previous study, we showed that ICV injection of AdCre in mice with floxed extracellular SOD (SOD3 flox mice) specifically deleted SOD3 in the SFO, but had no effect on SOD3 in peripheral tissues, suggesting that the adenovirus does not gain access to peripheral sites, when injected ICV. 18 We further showed that even intraperitoneal injection of the small amount of AdCre used for ICV injection had no effect on vascular SOD3 levels in this study. It is therefore unlikely that injection of AdCre in the present study had any direct effect on p22 phox expression in tissues outside the central nervous system. In the same study, we also found that the adenovirus expression after ICV injection was limited to the periventricular tissues, and predominantly in the SFO, and did not reach deeper regions of the brain. 18 It is therefore likely that in the present study, SFO-targeted ICV injection of AdCre caused excision of the p22 phox gene predominantly in the SFO, and not at other sites within the central nervous system. Deletion of p22 phox in the SFO corresponded with a loss of O 2 ·− production, as reflected by dihydroethidium staining, blunting of the hypertensive response to angiotensin II, and a marked attenuation in sympathetic outflow, as characterized by the low-frequency blood pressure variations. These findings are thus compatible with a critical role of ROS in modulation of neuronal signaling in SFO, in response to stimuli such as angiotensin II.
A striking finding in our study was that deletion of p22 phox in the SFO decreased mRNA levels of Nox4 and Nox2. The precise reason for this is unclear. It is possible that mRNA transcription or stability is redox regulated in neuronal cells. Although previously uninvestigated, it is also possible that p22 phox has functions other than simply acting as a docking subunit for the Nox subunits that could modulate expression of other genes. Additional studies of examining transcriptional and posttranscriptional regulation of Nox2 and Nox4 mRNA would be necessary to address this issue.
There is ample evidence that oxidative signaling in central cardiovascular control centers modulates sympathetic outflow. 11, 14, 30, 31 Increased oxidative stress in the SFO increases sympathetic outflow and moderately elevates blood pressure. 18 In elegant studies, Chan et al 32 showed that angiotensin II in the rostral venterolateral medulla increases O 2 ·− via NADPH oxidase activation and causes increased neural firing. In spontaneous hypertensive rats, a model of neurogenic hypertension characterized by increased sympathetic nervous activity, reduction of O 2 ·− in the rostral venterolateral medulla blunts hypertension. 31 In keeping with these data, power spectral analysis indicated that sympathetic outflow in response to angiotensin II is significantly diminished by deletion of p22 phox in the SFO, supporting the concept that NADPH oxidasederived O 2 ·− enhances neuronal firing in these centers. Recent studies from our laboratory have shown that T-cells are essential for the development of various forms of experimental hypertension. 33, 34 In these studies, we found that hypertension promotes accumulation of activated T-cells and macrophages in the perivascular fat of both large and small arteries. Our current findings are also compatible with a recent study in which anteroventral third ventricle lesions prevent T-cell activation and vascular inflammation. The virtual elimination of vascular inflammation after central deletion of p22 phox might be a consequence of simply preventing hypertension. In this regard, we have previously shown that lowering blood pressure with hydralazine also prevents vascular inflammation in response to either angiotensin II or norepinephrine infusion. 34 It is also possible that disruption of sympathetic stimulation reduces T-cell activation and vascular inflammation. In keeping with this concept, Ganta et al 35 have shown that angiotensin II stimulates cytokine production by splenocytes via sympathetic activation. Innate and adaptive immune cells possess both α-and β-adrenergic receptors, 36 and modulate immune functions such as antigen presentation by dendritic cells, clonal expansion of lymphocytes, migration, and cell trafficking.
Interestingly, the increase in vascular p22 phox , Nox2, and preproendothelin-1 caused by angiotensin II infusion was not affected by p22 phox deletion in the SFO. These results indicate that p22 phox , Nox2, and preproendothelin-1 are regulated by direct actions of angiotensin II on vascular cells, independent of blood pressure and sympathetic outflow, and are in keeping with studies in which angiotensin II induces expression of these genes in cultured vascular cells. These findings also suggest that blockade of angiotensin II production and its receptors could have additional benefit beyond blockade of sympathetic outflow.
Perspectives
This study definitively identifies a critical role of the NADPH oxidases, and by inference, a role for ROS derived from the NADPH oxidases, in the SFO in modulation of hypertension and the systemic inflammation caused by angiotensin II. Furthermore, our study suggests that therapeutic interventions that target this central site could prevent the untoward effects of this common disease.
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